Polar Capital Holdings’s Ocular Therapeutix OCUL Stock Holding History

Polar Capital Holdings’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37,790	Closed	-$187	–	462
2022 Q1	$187	Hold	37,790	–	–	﹤0.01%	423
2021 Q4	$263	Hold	37,790	–	–	﹤0.01%	408
2021 Q3	$378	Hold	37,790	–	–	﹤0.01%	341
2021 Q2	$536	Buy	37,790 +10,251	+37%	+$156K	﹤0.01%	339
2021 Q1	$452K	Hold	27,539	–	–	﹤0.01%	306
2020 Q4	$570K	Buy	+27,539	New	+$409K	﹤0.01%	304

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Polar Capital Holdings's OCUL Position: Q2 2022 in Review

Polar Capital Holdings sold out of Ocular Therapeutix (OCUL) in Q2 2022, closing a stake of 37,790 shares — an estimated $187 sold.

Polar Capital Holdings first reported a position in OCUL in Q4 2020 and held it in 6 quarters. The position peaked at $570K in Q4 2020. 123 funds tracked by Wall St. Rank hold OCUL as of Q2 2022.

Polar Capital Holdings reported no remaining Ocular Therapeutix position as of Q2 2022 after selling out during the quarter.
Polar Capital Holdings sold 37,790 Ocular Therapeutix shares in Q2 2022, an estimated $187.
Polar Capital Holdings first reported a position in Ocular Therapeutix in Q4 2020 and held it in 6 quarters.
Polar Capital Holdings's Ocular Therapeutix position peaked at $570K in Q4 2020.
123 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2022.

Based on Polar Capital Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.